Maia Biotechnology Stock Buy Hold or Sell Recommendation
| MAIA Stock | USD 2.46 0.20 8.85% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding MAIA Biotechnology is 'Cautious Hold'. Macroaxis provides MAIA Biotechnology buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding MAIA positions. The advice algorithm takes into account all of MAIA Biotechnology's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting MAIA Biotechnology's buy or sell advice are summarized below:
Real Value 4.72 | Target Price 11.75 | Hype Value 2.44 | Market Value 2.46 | Naive Value 2.23 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell MAIA Biotechnology given historical horizon and risk tolerance towards MAIA Biotechnology. When Macroaxis issues a 'buy' or 'sell' recommendation for MAIA Biotechnology, the advice is generated through an automated system that utilizes algorithms and statistical models.
MAIA |
Execute MAIA Biotechnology Buy or Sell Advice
The MAIA recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on MAIA Biotechnology. Macroaxis does not own or have any residual interests in MAIA Biotechnology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute MAIA Biotechnology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Good | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
MAIA Biotechnology Trading Alerts and Improvement Suggestions
| MAIA Biotechnology is way too risky over 90 days horizon | |
| MAIA Biotechnology appears to be risky and price may revert if volatility continues | |
| MAIA Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (19.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| MAIA Biotechnology currently holds about 8.15 M in cash with (13.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75. | |
| MAIA Biotechnology has a frail financial position based on the latest SEC disclosures | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from seekingalpha.com: MAIA Biotechnology announces 1M private placement |
MAIA Biotechnology Returns Distribution Density
The distribution of MAIA Biotechnology's historical returns is an attempt to chart the uncertainty of MAIA Biotechnology's future price movements. The chart of the probability distribution of MAIA Biotechnology daily returns describes the distribution of returns around its average expected value. We use MAIA Biotechnology price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of MAIA Biotechnology returns is essential to provide solid investment advice for MAIA Biotechnology.
| Mean Return | 1.18 | Value At Risk | -7.69 | Potential Upside | 12.67 | Standard Deviation | 6.19 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of MAIA Biotechnology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
MAIA Biotechnology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to MAIA Biotechnology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that MAIA Biotechnology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a MAIA stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.97 | |
β | Beta against NYSE Composite | 2.28 | |
σ | Overall volatility | 6.14 | |
Ir | Information ratio | 0.17 |
MAIA Biotechnology Volatility Alert
MAIA Biotechnology is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure MAIA Biotechnology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact MAIA Biotechnology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.MAIA Biotechnology Fundamentals Vs Peers
Comparing MAIA Biotechnology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze MAIA Biotechnology's direct or indirect competition across all of the common fundamentals between MAIA Biotechnology and the related equities. This way, we can detect undervalued stocks with similar characteristics as MAIA Biotechnology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of MAIA Biotechnology's fundamental indicators could also be used in its relative valuation, which is a method of valuing MAIA Biotechnology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare MAIA Biotechnology to competition |
| Fundamentals | MAIA Biotechnology | Peer Average |
| Return On Equity | -4.4 | -0.31 |
| Return On Asset | -1.29 | -0.14 |
| Current Valuation | 42.06 M | 16.62 B |
| Shares Outstanding | 20.58 M | 571.82 M |
| Shares Owned By Insiders | 21.42 % | 10.09 % |
| Shares Owned By Institutions | 3.85 % | 39.21 % |
| Number Of Shares Shorted | 845.08 K | 4.71 M |
| Price To Book | 92.37 X | 9.51 X |
| EBITDA | (15.86 M) | 3.9 B |
| Net Income | (19.77 M) | 570.98 M |
| Cash And Equivalents | 8.15 M | 2.7 B |
| Cash Per Share | 0.75 X | 5.01 X |
| Current Ratio | 2.78 X | 2.16 X |
| Book Value Per Share | 0.03 X | 1.93 K |
| Cash Flow From Operations | (13.07 M) | 971.22 M |
| Short Ratio | 1.47 X | 4.00 X |
| Earnings Per Share | (1.49) X | 3.12 X |
| Target Price | 12.63 | |
| Number Of Employees | 13 | 18.84 K |
| Market Capitalization | 50.63 M | 19.03 B |
| Total Asset | 7.57 M | 29.47 B |
| Retained Earnings | (63.98 M) | 9.33 B |
| Working Capital | 2.63 M | 1.48 B |
| Net Asset | 7.57 M |
Note: Acquisition by Louie Ngar Yee of 13365 shares of MAIA Biotechnology at 2.2 subject to Rule 16b-3 [view details]
MAIA Biotechnology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as MAIA . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About MAIA Biotechnology Buy or Sell Advice
When is the right time to buy or sell MAIA Biotechnology? Buying financial instruments such as MAIA Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2023 | 2024 (projected) | Short and Long Term Debt Total | 533.3K | 274.4K | Total Assets | 7.6M | 7.3M |
Use Investing Ideas to Build Portfolios
In addition to having MAIA Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Insurance Thematic Idea Now
Insurance
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Insurance theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Theme or any other thematic opportunities.
| View All Next | Launch |
Check out MAIA Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for MAIA Stock analysis
When running MAIA Biotechnology's price analysis, check to measure MAIA Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MAIA Biotechnology is operating at the current time. Most of MAIA Biotechnology's value examination focuses on studying past and present price action to predict the probability of MAIA Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MAIA Biotechnology's price. Additionally, you may evaluate how the addition of MAIA Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is MAIA Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Return On Assets (1.29) | Return On Equity (4.40) |
The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MAIA Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.